Abstract

Is heparin sufficient in non-ST-elevation acute coronary syndrome percutaneous coronary intervention?

Author(s): O Angeras, T Ramunddal, P Albertsson, D Erlinge & E Omerovic

Bivalirudin (Angiomax®, The Medicines Company, NJ, USA) is a direct-acting synthetic antithrombotic agent that has been approved as an alternative treatment to unfractionated heparin for patients with acute coronary syndromes who are undergoing percutaneous coronary intervention (PCI). Both European Society of Cardiology and American College of Cardiology/American Heart Association guidelines recommend this antithrombotic agent for the treatment of patients with non-ST-elevation acute coronary syndrome (NSTE-ACS) in the setting of PCI.